News & Updates

In patients with newly implanted ventricular assist devices (VAD), better leg extensor muscle strength (LEMS) at discharge may suggest a lower risk of rehospitalization, according to a recent Japan study.

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

Patients with cholesterol crystal embolism (CCE) endure poor prognoses, highlighting the need for better identification of high-risk patients before undergoing percutaneous coronary intervention (PCI), a recent study has found.

A shorter duration of anticoagulant therapy of 6 weeks is as effective in preventing recurrent thrombosis as the conventional 3-month treatment course without increasing the risk of bleeding in young patients aged below 21 years old with acute provoked venous thromboembolism, according to the Kids-DOTT* trial.

Treatment with colchicine appears to produce a significant reduction in the risk of major adverse cardiovascular events (MACE) in coronary artery disease patients who underwent percutaneous coronary intervention (PCI), according to the results of a systematic review and meta-analysis.